Senaparib capsules(20mg)

DRUG2 trials

Sponsors

Impact Therapeutics, Inc., Zhejiang Cancer Hospital

Conditions

Ovarian Cancer (OvCa)Solid Tumor

Phase 1

An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition

CompletedNCT07019194

Impact Therapeutics, Inc.Solid Tumor

Start: 2024-06-21End: 2024-07-15Updated: 2025-06-13

Unknown Phase

A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer

Not yet recruitingNCT07586449

Zhejiang Cancer HospitalOvarian Cancer (OvCa)

Start: 2026-06-10End: 2030-12-31Target: 500Updated: 2026-05-14